Session 2: The Convergence of Artificial Intelligence and Microfluidics

Chair: Sammy Datwani, Ph.D. (Systemic Bio)

Microfluidics permits the automated manipulation of fluids at the microscale with high throughput and spatiotemporal precision, enabling the generation of large, multidimensional datasets. Artificial intelligence (AI) provides a powerful predictive tool with the ability to learn from data. AI-produced outcomes have been proven comparable or even superior to the performance of human experts in drug design, material discovery, and personalized medicine. The goal of this session is to highlight cutting-edge technological innovations on the microscale integrated with AI/ML that together have the immense potential to reshape life science research and the clinical care paradigms.

Digital Enzyme Evolution™: Imperagen’s Digitalised Enzyme Engineering Platform Informed by Machine Learning
Andrew Currin, Ph.D. (Imperagen)

Modern AI-Powered Design for Medicinal Chemistry and Beyond
Max Jakobs, Ph.D. (DeepMirror)

AI-Empowered High-content Pooled Phenotypic Screening via Ghost Cytometry
Andy Wu, Ph.D. (ThinkCyte)